Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NIH Pilots Virtual Pharma Portfolio In Neurology

Executive Summary

With a last round of applications due Oct. 8, the Neurotherapeutics Network is hoping for increased industry participation in a portfolio of 20 projects in the hit-to-lead-optimization stage that will have access to CROs under contract to NIH. Projects that continue to meet milestones will be supported through proof-of-concept in humans.

You may also be interested in...

Getting Through To Autism: Seaside Pioneers New Drugs

Tiny Seaside Therapeutics is doing pioneering work to develop disease-modifying drugs for Autism Spectrum Disorders, a group of syndromes that not long ago was thought immutable and even blamed on bad parenting. By targeting molecular pathways associated with the single gene disorder fragile X syndrome, Seaside hopes to extrapolate its work to other “autisms” and help people most affected by those disorders learn to walk, talk, or even live independent lives.

Updated SBIR Grants May Already Need A Fix To Keep Up With The Times

Just as the Small Business Innovation Research program achieved a congressional fix for the knotty problem of letting companies with VC support apply for the “valley of death” grants, it may have fallen behind again with its de facto exclusion of virtual start-ups. Companies have until July 16 to comment on the program’s updated implementing regulation.

Trevena Scores NIH Grant For Research In Major Depression

The biotech has forged a partnership with NIH to discover and begin development of a biased ligand to the delta opioid receptor for the treatment of MDD.


Related Companies

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts